KR102194089B1 - 항산화 활성 및 미백 효과를 갖는 플렉시블 금속 패치 및 그 사용방법 - Google Patents
항산화 활성 및 미백 효과를 갖는 플렉시블 금속 패치 및 그 사용방법 Download PDFInfo
- Publication number
- KR102194089B1 KR102194089B1 KR1020190030701A KR20190030701A KR102194089B1 KR 102194089 B1 KR102194089 B1 KR 102194089B1 KR 1020190030701 A KR1020190030701 A KR 1020190030701A KR 20190030701 A KR20190030701 A KR 20190030701A KR 102194089 B1 KR102194089 B1 KR 102194089B1
- Authority
- KR
- South Korea
- Prior art keywords
- activity
- flexible metal
- antioxidant
- metal patch
- whitening
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229910052751 metal Inorganic materials 0.000 title claims abstract description 136
- 239000002184 metal Substances 0.000 title claims abstract description 135
- 230000002087 whitening effect Effects 0.000 title claims abstract description 57
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 54
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 44
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 claims abstract description 31
- 230000007760 free radical scavenging Effects 0.000 claims abstract description 25
- 239000002537 cosmetic Substances 0.000 claims abstract description 21
- 150000001875 compounds Chemical class 0.000 claims abstract description 18
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 11
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 10
- 229910052742 iron Inorganic materials 0.000 claims abstract description 7
- 229910052710 silicon Inorganic materials 0.000 claims abstract description 7
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 7
- 229910052726 zirconium Inorganic materials 0.000 claims abstract description 7
- 229910052748 manganese Inorganic materials 0.000 claims abstract description 5
- 239000011777 magnesium Substances 0.000 claims description 45
- 230000000694 effects Effects 0.000 claims description 33
- 229910052749 magnesium Inorganic materials 0.000 claims description 29
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 28
- 230000002401 inhibitory effect Effects 0.000 claims description 26
- 102000003425 Tyrosinase Human genes 0.000 claims description 19
- 108060008724 Tyrosinase Proteins 0.000 claims description 19
- 239000011575 calcium Substances 0.000 claims description 18
- 238000004519 manufacturing process Methods 0.000 claims description 17
- 239000011701 zinc Substances 0.000 claims description 17
- 239000000126 substance Substances 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 15
- 229920000877 Melamine resin Polymers 0.000 claims description 14
- JDSHMPZPIAZGSV-UHFFFAOYSA-N melamine Chemical compound NC1=NC(N)=NC(N)=N1 JDSHMPZPIAZGSV-UHFFFAOYSA-N 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 14
- 238000009472 formulation Methods 0.000 claims description 12
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 claims description 12
- 229960000401 tranexamic acid Drugs 0.000 claims description 12
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 10
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 9
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 6
- 238000000354 decomposition reaction Methods 0.000 claims description 6
- 239000011734 sodium Substances 0.000 claims description 6
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 5
- 229920000642 polymer Polymers 0.000 claims description 5
- 239000000919 ceramic Substances 0.000 claims description 4
- 239000011572 manganese Substances 0.000 claims description 4
- 229910052759 nickel Inorganic materials 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 229910017706 MgZn Inorganic materials 0.000 claims description 3
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 claims description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 3
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims description 3
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 claims description 3
- 229910052733 gallium Inorganic materials 0.000 claims description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052737 gold Inorganic materials 0.000 claims description 3
- 239000010931 gold Substances 0.000 claims description 3
- 229910052750 molybdenum Inorganic materials 0.000 claims description 3
- 239000011733 molybdenum Substances 0.000 claims description 3
- 229910052758 niobium Inorganic materials 0.000 claims description 3
- 239000010955 niobium Substances 0.000 claims description 3
- GUCVJGMIXFAOAE-UHFFFAOYSA-N niobium atom Chemical compound [Nb] GUCVJGMIXFAOAE-UHFFFAOYSA-N 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- 239000011591 potassium Substances 0.000 claims description 3
- 229910052711 selenium Inorganic materials 0.000 claims description 3
- 239000011669 selenium Substances 0.000 claims description 3
- 239000010703 silicon Substances 0.000 claims description 3
- 229910052709 silver Inorganic materials 0.000 claims description 3
- 239000004332 silver Substances 0.000 claims description 3
- 229910052712 strontium Inorganic materials 0.000 claims description 3
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 claims description 3
- 229910052715 tantalum Inorganic materials 0.000 claims description 3
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 claims description 3
- 229910052719 titanium Inorganic materials 0.000 claims description 3
- 239000010936 titanium Substances 0.000 claims description 3
- 230000003064 anti-oxidating effect Effects 0.000 claims 3
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims 1
- 239000000284 extract Substances 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 46
- 210000003491 skin Anatomy 0.000 description 32
- 235000006708 antioxidants Nutrition 0.000 description 30
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 19
- 238000011156 evaluation Methods 0.000 description 19
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 18
- 239000000047 product Substances 0.000 description 16
- 239000000463 material Substances 0.000 description 13
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 11
- 230000002292 Radical scavenging effect Effects 0.000 description 10
- 238000005259 measurement Methods 0.000 description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 229910045601 alloy Inorganic materials 0.000 description 6
- 239000000956 alloy Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 150000002739 metals Chemical class 0.000 description 6
- 208000003351 Melanosis Diseases 0.000 description 5
- 239000003708 ampul Substances 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 239000000049 pigment Substances 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 206010067484 Adverse reaction Diseases 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 239000002211 L-ascorbic acid Substances 0.000 description 4
- 229910001297 Zn alloy Inorganic materials 0.000 description 4
- 230000006838 adverse reaction Effects 0.000 description 4
- 229960005070 ascorbic acid Drugs 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 206010008570 Chloasma Diseases 0.000 description 3
- 235000000069 L-ascorbic acid Nutrition 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 210000002780 melanosome Anatomy 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 2
- 206010014970 Ephelides Diseases 0.000 description 2
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 108010051081 dopachrome isomerase Proteins 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000008099 melanin synthesis Effects 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 description 2
- 229920001610 polycaprolactone Polymers 0.000 description 2
- 239000004632 polycaprolactone Substances 0.000 description 2
- 239000000622 polydioxanone Substances 0.000 description 2
- 239000004633 polyglycolic acid Substances 0.000 description 2
- 229950008885 polyglycolic acid Drugs 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000037384 skin absorption Effects 0.000 description 2
- 231100000274 skin absorption Toxicity 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 108010014402 tyrosinase-related protein-1 Proteins 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- VIYKYVYAKVNDPS-HKGPVOKGSA-N (2s)-2-azanyl-3-[3,4-bis(oxidanyl)phenyl]propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 VIYKYVYAKVNDPS-HKGPVOKGSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 1
- 238000001295 Levene's test Methods 0.000 description 1
- 229910000861 Mg alloy Inorganic materials 0.000 description 1
- 229910019440 Mg(OH) Inorganic materials 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 206010036229 Post inflammatory pigmentation change Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 229910009378 Zn Ca Inorganic materials 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 239000012496 blank sample Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000005016 dendritic process Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 238000007489 histopathology method Methods 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910000765 intermetallic Inorganic materials 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 150000007524 organic acids Chemical group 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000007348 radical reaction Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000013215 result calculation Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- JBQYATWDVHIOAR-UHFFFAOYSA-N tellanylidenegermanium Chemical compound [Te]=[Ge] JBQYATWDVHIOAR-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0208—Tissues; Wipes; Patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/24—Phosphorous; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/25—Silicon; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/27—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/91—Graft copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/91—Injection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
화학식 1
MgaXb
화학식 1에서 a 및 b 는 각 성분의 중량%로서, a+b=100중량%이고, 5〈 a〈100이고, X는 Zn, Ca, Fe, Mn, Si, Na, Zr, Ce, Ag 및 P로 구성된 군에서 선택되는 단독 또는 이들의 조합임.
Description
도 2는 본 발명에 따른 플렉시블 금속 패치에 대한 메탄올 용액의 농도별 DPPH 라디칼 소거활성도(%) 그래프로서, 3개 웰(well)에 대한 각각의 결과 그래프.
도 3은 본 발명에 따른 플렉시블 금속 패치에 대한 DPPH 라디칼 소거활성도 평가에서 양성대조군으로 이용된 L-아스코르브산의 메탄올 용액에 대한 농도별 DPPH 라디칼 소거활성도(%) 그래프로서, 3개 웰(well)에 대한 각각의 결과 그래프.
도 4는 본 발명에 따른 플렉시블 금속 패치의 미백 기능성 평가에 있어서 대조군으로 이용된 패치와 앰플 병용 시험군에 대한 임상실험 결과에 있어서 피부밝기 개선도 결과 그래프.
도 5는 본 발명에 따른 플렉시블 금속 패치의 미백 기능성 평가에 있어서 패치 단독 시험군에 대한 임상실험 결과에 있어서 피부밝기 개선도 결과 그래프.
시험군 | 시험물질명 | 처리농도(%) |
G1(시험물질) | 마그네슘 패치 | 1, 2.5, 5, 10 |
G2(양성대조물질) | L-아스코르브산 | 0.0005, 0.001, 0.0015, 0.002 |
시험군 | 웰(well)의 갯수 | 농도(%) | OD517 (평균 ± 표준편차) |
DPPH 자유라디칼 소거 활성(%) (평균±표준편차) |
G1 | 3 | 0 | 0.859 ± 0.041 | - |
3 | 1 | 0.758 ± 0.017 | 11.58 ± 4.69 | |
3 | 2.5 | 0.740 ± 0.014 | 13.73 ± 4.22 | |
3 | 5 | 0.620 ± 0.008 | 27.69 ± 2.57 | |
3 | 10 | 0.622 ± 0.017 | 27.55 ± 3.06 | |
G2 | 3 | 0 | 0.610 ± 0.029 | - |
3 | 0.0005 | 0.482 ± 0.024 | 20.96 ± 2.79 | |
3 | 0.001 | 0.364 ± 0.027 | 40.38 ± 1.61 | |
3 | 0.0015 | 0.210 ± 0.023 | 65.57 ± 2.21 | |
3 | 0.002 | 0.102 ± 0.013 | 83.24 ± 1.48 |
구분 | 패치와 앰플 동시 사용군 | 패치 단독 사용군 |
사용 전 | 58.755 ± 2.190 | 58.955 ± 2.196 |
사용 2주 후 | 59.043 ± 2.287 | 59.494 ± 2.218 |
사용 4주 후 | 59.082 ± 2.133 | 59.460 ± 2.013 |
사용 8주 후 | 59.573 ± 2.278 | 59.551 ± 2.091 |
사용 중단 2주 후 | 59.397 ± 1.920 | 59.378 ± 1.948 |
구분 | 0.001* | 0.001* |
사용 2주 후 - 사용 전 | 1.000 | 0.053 |
사용 4주 후 - 사용 전 | 1.000 | 0.013* |
사용 8주 후 - 사용 전 | 0.001* | 0.006* |
사용 중단 2주후 -사용 8주후 | 1.000 | 0.516 |
Claims (15)
- 다음 화학식 1로 표시되는 생체분해성 금속을 포함하는, DPPH 자유라디칼 소거활성, 항산화 및 미백 활성을 갖는 플렉시블 금속 패치.
[화학식 1]
MgaXb
화학식 1에서 a 및 b 는 각 성분의 중량%로서, a+b=100중량%이고, 5〈 a〈100이고, X는 Zn, Ca, Fe, Mn, Si, Na, Zr, Ce, Ag 및 P로 구성된 군에서 선택되는 단독 또는 이들의 조합임.
- 제 1 항에 있어서, 상기 생체분해성 금속은, 화학식 1에서 90≤ a〈100를 만족하는 것임을 특징으로 하는 DPPH 자유라디칼 소거활성, 항산화 및 미백 활성을 갖는 플렉시블 금속 패치.
- 제 1 항에 있어서, 상기 생체분해성 금속은 순도 95% 이상의 Mg인 것을 특징으로 하는 DPPH 자유라디칼 소거활성, 항산화 및 미백 활성을 갖는 플렉시블 금속 패치.
- 제 1 항에 있어서, 상기 생체분해성 금속은 2 이상의 금속 상(phase)이 갈바닉 회로를 생성하여 분해속도가 가속화되는 것을 특징으로 하는 DPPH 자유라디칼 소거활성, 항산화 및 미백 활성을 갖는 플렉시블 금속 패치.
- 제 4 항에 있어서, 상기 생체분해성 금속은 Mg2Ca 상을 포함하는 것을 특징으로 하는 DPPH 자유라디칼 소거활성, 항산화 및 미백 활성을 갖는 플렉시블 금속 패치.
- 제 4 항에 있어서, 상기 생체분해성 금속은 MgZn 상을 포함하는 것을 특징으로 하는 DPPH 자유라디칼 소거활성, 항산화 및 미백 활성을 갖는 플렉시블 금속 패치.
- 제 4 항에 있어서, 상기 생체분해성 금속은 Ca2Mg6Zn3 상을 포함하는 것을 특징으로 하는 DPPH 자유라디칼 소거활성, 항산화 및 미백 활성을 갖는 플렉시블 금속 패치.
- 제 1 항에 있어서, 상기 생체분해성 금속은 금속 표면에 다른 종류의 제2의 금속, 폴리머 또는 세라믹이 코팅된 것을 특징으로 하는 DPPH 자유라디칼 소거활성, 항산화 및 미백 활성을 갖는 플렉시블 금속 패치.
- 제 8 항에 있어서, 상기 제2의 금속은 나트륨, 마그네슘, 칼륨, 철, 니켈, 아연, 갈륨, 셀레늄, 스트론튬, 지르코늄, 몰리브덴, 니오븀, 탄탈륨, 타이타늄, 규소, 은, 금, 망간 및 칼슘으로 구성된 군에서 선택되는 1종 이상의 금속인 것을 특징으로 하는 DPPH 자유라디칼 소거활성, 항산화 및 미백 활성을 갖는 플렉시블 금속 패치.
- 제 1 항 내지 제 9 항 중 어느 한 항에 있어서, 플렉시블 금속 패치는 마이크로니들을 포함하는 패치인 것임을 특징으로 하는 DPPH 자유라디칼 소거활성, 항산화 및 미백 활성을 갖는 플렉시블 금속 패치.
- 제 1 항의 플렉시블 금속 패치; 및
티로시나아제 활성 억제 내지 멜라민 생성 억제 효과를 갖는 화합물을 포함하는 화장품적 제형으로 이루어진,
DPPH 자유라디칼 소거활성, 항산화 및 미백 활성을 갖는 플렉시블 금속 패치를 포함하는 화장품 패키지.
- 제 11 항에 있어서, 티로시나아제 활성 억제 내지 멜라민 생성 억제 효과를 갖는 화합물은 트라넥삼산(tranexamic acid)을 포함하는 것을 특징으로 하는,
DPPH 자유라디칼 소거활성, 항산화 및 미백 활성을 갖는 플렉시블 금속 패치를 포함하는 화장품 패키지.
- 제 1 항의 플렉시블 금속 패치를 피부에 부착하는 단계를 포함하는,
DPPH 자유라디칼 소거활성, 항산화 및 미백 활성을 갖는 플렉시블 금속 패치의 비치료적 사용방법.
- 제 13 항에 있어서, 플렉시블 금속 패치를 부착하기 전 또는 부착한 후 티로시나아제 활성 억제 내지 멜라민 생성 억제 효과를 갖는 화합물을 포함하는 화장품적 제형을 도포하는 단계를 포함하는,
DPPH 자유라디칼 소거활성, 항산화 및 미백 활성을 갖는 플렉시블 금속 패치의 비치료적 사용방법.
- 제 14 항에 있어서, 티로시나아제 활성 억제 내지 멜라민 생성 억제 효과를 갖는 화합물은 트라넥삼산(tranexamic acid)을 포함하는 것을 특징으로 하는,
DPPH 자유라디칼 소거활성, 항산화 및 미백 활성을 갖는 플렉시블 금속 패치의 비치료적 사용방법.
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190030701A KR102194089B1 (ko) | 2019-03-18 | 2019-03-18 | 항산화 활성 및 미백 효과를 갖는 플렉시블 금속 패치 및 그 사용방법 |
PCT/KR2020/003333 WO2020189944A1 (ko) | 2019-03-18 | 2020-03-10 | 항산화 활성 및 미백 효과를 갖는 플렉시블 금속 패치 및 그 사용방법 |
JP2021555559A JP2022526095A (ja) | 2019-03-18 | 2020-03-10 | 抗酸化活性及び美白効果を有するフレキシブル金属パッチとその使用方法 |
US17/440,742 US20220168193A1 (en) | 2019-03-18 | 2020-03-10 | Flexible metal patch having antioxidant activity and brightening effect and method for using same |
CN202080021093.XA CN113573684A (zh) | 2019-03-18 | 2020-03-10 | 具有抗氧化活性及美白效果的柔性金属贴片及其使用方法 |
EP20773454.2A EP3925594A4 (en) | 2019-03-18 | 2020-03-10 | Flexible metal patch having antioxidant activity and whitening effect and method for using same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190030701A KR102194089B1 (ko) | 2019-03-18 | 2019-03-18 | 항산화 활성 및 미백 효과를 갖는 플렉시블 금속 패치 및 그 사용방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20200111011A KR20200111011A (ko) | 2020-09-28 |
KR102194089B1 true KR102194089B1 (ko) | 2020-12-22 |
Family
ID=72520426
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020190030701A Active KR102194089B1 (ko) | 2019-03-18 | 2019-03-18 | 항산화 활성 및 미백 효과를 갖는 플렉시블 금속 패치 및 그 사용방법 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20220168193A1 (ko) |
EP (1) | EP3925594A4 (ko) |
JP (1) | JP2022526095A (ko) |
KR (1) | KR102194089B1 (ko) |
CN (1) | CN113573684A (ko) |
WO (1) | WO2020189944A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024063521A1 (ko) | 2022-09-20 | 2024-03-28 | 랩앤피플주식회사 | 생체분해성 금속을 포함하는 자가 전류 발생 피부 적용 패치 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3935932A1 (de) * | 2020-07-07 | 2022-01-12 | Andreas Stihl AG & Co. KG | Schneidmesser für einen schneidkopf und schneidkopf für eine motorsense |
USD1053368S1 (en) * | 2024-06-05 | 2024-12-03 | Shenzhen Hengdasheng Technology Co., Ltd. | Acne patch |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101352565B1 (ko) | 2012-01-30 | 2014-01-17 | 서강대학교산학협력단 | 마그네슘 프로토포르피린 ix를 함유한 과산화수소 제거제 및 이를 이용한 과산화수소 독성의 저감 방법 |
KR101483207B1 (ko) | 2014-06-25 | 2015-01-22 | 한국지질자원연구원 | 고흡수성 마그네슘 복합체의 제조방법 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7479133B2 (en) * | 2003-06-30 | 2009-01-20 | Johnson & Johnson Consumer Companies, Inc. | Methods of treating acne and rosacea with galvanic generated electricity |
EP1870094A1 (en) * | 2005-04-13 | 2007-12-26 | Shiseido Company, Limited | Antiwrinkle agent |
US20060253079A1 (en) * | 2005-04-25 | 2006-11-09 | Mcdonough Justin | Stratum corneum piercing device |
CN101951929A (zh) * | 2007-12-28 | 2011-01-19 | 水株式会社 | 用于治疗或预防的外用剂 |
KR101219520B1 (ko) | 2008-03-13 | 2013-01-08 | 주식회사 미셀 바이오 | 항염증, 항산화 또는 항세균 조성물 |
JP5584202B2 (ja) * | 2008-05-21 | 2014-09-03 | セラジェクト, インコーポレイテッド | 固溶体穿孔器パッチの製造方法及びその使用 |
KR20110065391A (ko) * | 2009-12-07 | 2011-06-15 | 유앤아이 주식회사 | 마그네슘 합금을 이용한 약물 전달체 |
KR101823036B1 (ko) * | 2010-03-31 | 2018-01-31 | (주)아모레퍼시픽 | 멜라닌 색소 생성 억제제 및 이를 함유하는 화장료 조성물 |
US20130323190A1 (en) * | 2011-02-17 | 2013-12-05 | Hydrogen Health Medical Labo Co., Ltd. | Composition generating hydrogen |
KR101351187B1 (ko) | 2013-07-10 | 2014-01-14 | 전라남도 | 미역귀를 이용한 항산화 기능성 화장품 원료추출방법 및 이를 이용한 항산화기능성 화장품 |
KR20150011260A (ko) * | 2013-07-22 | 2015-01-30 | (주)아모레퍼시픽 | 패치 및 화장료 조성물을 포함하는 미용 키트 및 미용 방법 |
KR101492196B1 (ko) * | 2013-09-06 | 2015-03-05 | 주식회사 아미코스메틱 | 백복령, 유백피 및 감초의 혼합 추출물을 포함하는 피부 미백용 화장료 조성물 |
KR102517754B1 (ko) * | 2015-04-29 | 2023-04-04 | 주식회사 엘지생활건강 | 트라넥삼산 약물 전달용 용해성 미세바늘 패치 |
KR20170115429A (ko) * | 2016-04-07 | 2017-10-17 | 랩앤피플주식회사 | 생체분해성 금속을 이용한 마이크로 니들 |
KR101885224B1 (ko) | 2016-05-26 | 2018-09-11 | 대봉엘에스 주식회사 | 금불초, 삼지구엽초 및 마디풀 복합 추출물 제조방법, 및 이로부터 제조된 기능성 화장료 조성물 |
US11241563B2 (en) * | 2016-12-22 | 2022-02-08 | Johnson & Johnson Consumer Inc. | Microneedle arrays and methods for making and using |
KR101947624B1 (ko) | 2016-12-29 | 2019-02-14 | 랩앤피플주식회사 | 멀티형 마이크로 니들 |
KR101811411B1 (ko) | 2017-03-02 | 2017-12-21 | (주)지에프씨 | 딱지꽃 발효 추출물을 포함하는 화장료 조성물 및 이의 제조 방법 |
-
2019
- 2019-03-18 KR KR1020190030701A patent/KR102194089B1/ko active Active
-
2020
- 2020-03-10 US US17/440,742 patent/US20220168193A1/en not_active Abandoned
- 2020-03-10 CN CN202080021093.XA patent/CN113573684A/zh active Pending
- 2020-03-10 WO PCT/KR2020/003333 patent/WO2020189944A1/ko unknown
- 2020-03-10 EP EP20773454.2A patent/EP3925594A4/en active Pending
- 2020-03-10 JP JP2021555559A patent/JP2022526095A/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101352565B1 (ko) | 2012-01-30 | 2014-01-17 | 서강대학교산학협력단 | 마그네슘 프로토포르피린 ix를 함유한 과산화수소 제거제 및 이를 이용한 과산화수소 독성의 저감 방법 |
KR101483207B1 (ko) | 2014-06-25 | 2015-01-22 | 한국지질자원연구원 | 고흡수성 마그네슘 복합체의 제조방법 |
Non-Patent Citations (1)
Title |
---|
Journal of Cosmetic Dermatology, 12, 57--66 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024063521A1 (ko) | 2022-09-20 | 2024-03-28 | 랩앤피플주식회사 | 생체분해성 금속을 포함하는 자가 전류 발생 피부 적용 패치 |
Also Published As
Publication number | Publication date |
---|---|
KR20200111011A (ko) | 2020-09-28 |
US20220168193A1 (en) | 2022-06-02 |
EP3925594A1 (en) | 2021-12-22 |
JP2022526095A (ja) | 2022-05-23 |
WO2020189944A1 (ko) | 2020-09-24 |
CN113573684A (zh) | 2021-10-29 |
EP3925594A4 (en) | 2023-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102194089B1 (ko) | 항산화 활성 및 미백 효과를 갖는 플렉시블 금속 패치 및 그 사용방법 | |
KR20190075033A (ko) | 생체분해성 금속을 이용한 마이크로 니들 | |
EP2200619B1 (en) | Electricity-generating particulates and the use thereof | |
US20100272789A1 (en) | External medicine for treatment or prevention | |
US20070190175A1 (en) | Skin care composition for dermatological disorders | |
EP4272726A1 (en) | Cosmetic composition comprising dead lactic acid bacteria lactobacillus plantarum mass or culture of lactic acid bacteria for preventing or alleviating skin aging | |
US9000049B2 (en) | Combination of lycopene, polyphenol, and vitamins for the care of keratin materials | |
EP3854316B1 (en) | Thread embedding therapy rope and thread embedding therapy needle apparatus comprising same | |
WO2005067885A1 (en) | Skin whitening composition having synergic whitening effect | |
KR20120095049A (ko) | 피부 미백용 화장료 조성물 | |
Wahab et al. | Combination of topical and oral glutathione as a skin‐whitening agent: a double‐blind randomized controlled clinical trial | |
CN107296768A (zh) | 一种含红景天提取物和活性多肽组合的美白祛斑化妆品 | |
Fonseca et al. | Antiaging effects of a skin care formulation containing nanoencapsulated antioxidants: A clinical, in vitro, and ex vivo study | |
Lowe | Arterial embolization caused by injection of hyaluronic acid (Restylane). | |
EP3782615A1 (en) | Patch for alleviation and prevention of acne | |
KR20090091505A (ko) | 산소수를 함유하는 피부 미백용 화장료 조성물 | |
KR102201385B1 (ko) | 피부 미백용 조성물 및 이를 이용한 미백용 화장품 | |
CN107802880A (zh) | 一种抗凝血护理液、其制备方法以及抗凝血卫生巾 | |
KR102702839B1 (ko) | 피부 미백 및 주름방지 효과가 증진된 식물성 오일을 함유하는 기능성 화장품 조성물 | |
Manggabarani et al. | Effectiveness of glutathione (gsh) 2%, tocopheryl acetate 1%, and magnesium ascorbyl phosphate 3% combination cream compared with hydroquinone 4% cream as a skin lightening agent: a randomised study | |
WO2025073787A1 (en) | Non-therapeutic and therapeutic use of hydroxycinnamic acid & derivatives | |
KR101754556B1 (ko) | 수베르산 또는 이의 염을 유효성분으로 함유하는 피부보습 개선 또는 피부탄력 증진 효과를 갖는 조성물 | |
Malankar et al. | Melatonin: A Paradigm Shift in the Management of Melasma | |
CN110464669A (zh) | 一种美白剂及其用途、美白用化妆品和美白用医药产品 | |
KR20150144197A (ko) | 카다모닌을 함유하는 액정 유화 화장료 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20190318 |
|
PA0201 | Request for examination | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20200528 Patent event code: PE09021S01D |
|
PG1501 | Laying open of application | ||
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20201109 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20201216 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20201216 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
PR1001 | Payment of annual fee |
Payment date: 20231122 Start annual number: 4 End annual number: 4 |
|
PR1001 | Payment of annual fee |
Payment date: 20241111 Start annual number: 5 End annual number: 5 |